Professor Zeng Jia’s Research Team Achieving Original Research Results

Recently, the original research results of Professor Zeng Jia’s research team from School of Life Science,HNUST, have been published in the international leading journals J. Biol. Chem and Cancer Research (J. Biol. Chem., 2018, 292, 3800-3809; J. Biol. Chem., 2020, 295, 10168-10179; Cancer Res., 2021, doi: 10.1158/0008-5472.CAN-20-1954; J. Biol. Chem., 2021, doi:10.1016/j.jbc.2021.100622). Dr. Deng Senwen and graduate student Li Ping, Chen Xiaocui, Shang Lin, Zhang Xiao and so on, are the first or co-first authors of these papers, and Professor Zeng Jia is the corresponding author. And it is known that J. Biol. Chem is the journal of American Society for Biochemistry and Molecular Biology and Cancer Research is the journal of American Cancer Society. Both of them are among the first 68 leading journals included in the Nature Index.

In the past 3 years, Professor Zeng Jia’s research team, through countless experiments, has made a series of original innovative research results on the correlative mechanism of peroxisomal fatty acid oxidation and metabolic diseases, which not only provide important experimental evidence and mechanism innovation for the full revelation of the core mechanism of metabolic diseases and tumorigenesis caused by abnormal fatty acid metabolism, but also new therapeutic targets and validation compounds for the development of original drugs for the treatment of metabolic diseases such as diabetes and fatty liver.

Professor Zeng Jia’s research team, around the correlative mechanism of fatty acid oxidation and metabolic diseases, has carried out in-depth researches on the biosynthesis of peroxisomal fatty acid oxidation and cholesterol, the regulatory mechanism of fatty acid metabolism and glucose synthesis, etc., which provide more sufficient experimental evidence and mechanism innovation for the full revelation of initiation mechanism of metabolic diseases and related complications.

The research team actively seeks opportunities to cooperate with large pharmaceutical companies at home and abroad in the field of drug for metabolic disease. So far, a number of multinational pharmaceutical companies have expressed their willingness to conduct collaborative research with the team. The research team will further connect with drug research and development enterprises, in the hope that these research results can be applied to clinical drug research and development as soon as possible and contribute to the implementation of the national independent innovation strategy.

(Translated by Jiang Xiaofeng)